As for the nuclear functions of GAPDH available reports indicate that GAPDH might be involved in both pro-apoptotic and oncogenic processes (Seidler, [46]). also indicate that intracellular ATP is usually a critical determinant of chemoresistance. Under hypoxic conditions where glycolysis remains the predominant energy generating pathway sensitizing malignancy cells would require intracellular depletion of ATP by inhibition of glycolysis. Together, the oncogenic regulation of glycolysis and multifaceted functions of glycolytic components underscore the biological significance of tumor Thiamet G glycolysis. Thus targeting glycolysis remains attractive for therapeutic intervention. Several preclinical investigations have indeed exhibited the effectiveness of this therapeutic approach thereby supporting its scientific rationale. Recent reviews have provided a wealth of information around the biochemical targets of glycolysis and their inhibitors. The objective of this evaluate is to present the most recent research around the cancer-specific role of glycolytic enzymes including Thiamet G their non-glycolytic functions in order to explore the potential for therapeutic opportunities. Further, we discuss the translational potential of emerging drug candidates in light of technical improvements in treatment modalities such as image-guided targeted delivery of malignancy therapeutics. Keywords:Glycolysis, Antiglycolytic brokers, Cancer metabolism, Chemotherapy == Introduction == Glucose metabolism in malignancy cells is primarily characterized by two major biochemical events: (i) increased glucose uptake and Thiamet G (ii) aerobic glycolysis, the process of conversion of glucose into pyruvate eventually resulting in the production of lactate (fermentation). The former has already been exploited clinically to diagnose malignancy and assess tumor response through the utilization of radiolabeled glucose analog,18Fluoro-deoxyglucose (FDG) Thiamet G in positron emission tomography (PET). PET imaging, combined with computed tomography (CT), plays an indispensable role in modern diagnostic oncology [1]. But it is the notion that tumor glycolysis could be used as a potential target for therapy that remain the most intriguing. The presence of a link between aerobic glycolysis (i.e. glycolysis in the presence of oxygen) and tumorigenesis has been known for several decades ever since the German scientist Otto Warburg proposed the Rabbit Polyclonal to SLC27A4 Warburg hypothesis known as the Warburg effect [2,3]. Yet, the underlying mechanistic details relevant to the causes and effects of such metabolic phenotype remained unclear. Conceptual advances in the past decades have improved our understanding around the biological significance of tumor metabolism [4]. As a result, deregulated or altered energy metabolism has been acknowledged as one of the hallmarks of malignancy [5]. It is progressively obvious that oncogenes and tumor suppressors regulate altered energy metabolism. Oncogenic mutations culminate in the up-regulation of glucose transporters (e.g. GLUT 1, GLUT 3) [6,7] thus facilitating increased glucose consumption by malignancy cells, which in turn increases the rate of glucose metabolism. Conversely, the glycolytic/metabolic phenotype confers selective advantage to malignancy cells by supporting uninterrupted growth. For example, a higher glycolytic rate in tumor cells has been Thiamet G shown to promote resistance to chemotherapeutics. In the cervical malignancy cell collection, HeLa for example, the enzyme pyruvate dehydrogenase kinase (PDK) isoforms PDK1 and PDK3 have been demonstrated to provide resistance to chemotherapeutics [8]. Similarly, in the colon carcinoma cell collection, LoVo it has been exhibited that increased aerobic lactate production (glycolysis) correlated with drug resistance [9]. Thus, interrupting or possibly disrupting tumor glycolysis will impact tumor growth by energy depletion as well as sensitization to therapeutics especially, in light of the recent reports that have elucidated cancer-specific advantages of aerobic glycolysis [10-13]. Several authors have delineated a wealth of information around the biochemical targets of glycolysis and their potent antagonists or inhibitors with encouraging anticancer effects (refer reviews [14-18]). Our goal in this evaluate is to discuss the cancer-specific intricacies and advantages of glycolysis in the light of recent research underscoring the clinical relevance of targeting it for malignancy therapy. == Glycolysis in malignancy == The fact that malignancy cells express the glycolytic phenotype has long been known (refer review, [19]). However, until recently, the dependence on such a phenotype remained unclear. In an elegant statement, Bonnet et al. [20] exhibited that reversing the glycolytic phenotype to oxidative phosphorylation (OXPHOS) in malignancy cells resulted in the induction of cell death. Further, when the mitochon-drial-K+channel axis of malignancy cells is usually suppressed, a mere restoration of mitochondrial-K+channel function is sufficient to promote apoptosis. This statement supports two major hypotheses, (i) reversal of the glycolytic phenotype to oxidative phosphorylation can promote malignancy cell death and (ii) glycolysis can facilitate tumor growth despite a suppressed mitochondria-K+channel axis. Understandably, the metabolic switch from mitochondrial.